ArticleFrontiers in medicine2023

Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China.

Hongbin Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.